Payment overview · 2025
General Payments
$515.67
23 reported records · 13 companies
Healthcare provider profile · identity verified
E Arthur Franklin, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MEMPHIS, TN · NPI 1467416149
Verified facts
What the public records show
CMS Open Payments records show E Arthur Franklin, MD received $515.67 in general payments during 2025 across 23 reported records.
Abbott Laboratories accounted for 17.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $88.95 | 17.2% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $81.75 | 15.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $71.06 | 13.8% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.39 | 9.2% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $35.46 | 6.9% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $34.11 | 6.6% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $33.27 | 6.5% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $32.58 | 6.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $21.64 | 4.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.72 | 3.8% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $17.37 | 3.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.71 | 3.2% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.66 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $515.67 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $81.75 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $71.06 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $50.09 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $34.11 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $33.27 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $32.58 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $32.58 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $21.64 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.55 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $15.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 58 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 69 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
44 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
58 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
69 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 386 | 121 |
| Levothyroxine Sodium | Levothyroxine Sodium | 385 | 121 |
| Losartan Potassium | Losartan Potassium | 363 | 118 |
| Amlodipine Besylate | Amlodipine Besylate | 341 | 115 |
| Omeprazole | Omeprazole | 299 | 106 |
| Pantoprazole Sodium | Pantoprazole Sodium | 230 | 71 |
| Simvastatin | Simvastatin | 219 | 65 |
| Lisinopril | Lisinopril | 199 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 193 | 64 |
| Alprazolam | Alprazolam | 182 | 58 |
| Meloxicam | Meloxicam | 174 | 68 |
| Zolpidem Tartrate | Zolpidem Tartrate | 174 | 54 |
| Metformin Hcl | Metformin Hcl | 169 | 54 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 163 | 53 |
| Gabapentin | Gabapentin | 160 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 159 | 52 |
| Potassium Chloride | Potassium Chloride | 155 | 51 |
| Sertraline Hcl | Sertraline Hcl | 147 | 39 |
| Montelukast Sodium | Montelukast Sodium | 134 | 42 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 132 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 114 | 41 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 105 | 37 |
| Glimepiride | Glimepiride | 102 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 102 | 32 |
| Eliquis | Apixaban | 101 | 26 |
| Trazodone Hcl | Trazodone Hcl | 96 | 28 |
| Allopurinol | Allopurinol | 89 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 52 |
| Azithromycin | Azithromycin | 82 | 74 |
| Furosemide | Furosemide | 80 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 73 | 21 |
| Clonazepam | Clonazepam | 71 | 16 |
| Carvedilol | Carvedilol | 69 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 69 | 61 |
| Ozempic | Semaglutide | 69 | 13 |
| Warfarin Sodium | Warfarin Sodium | 68 | 17 |
| Tramadol Hcl | Tramadol Hcl | 67 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | 23 |
| Atenolol | Atenolol | 65 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 63 | 23 |
| Mounjaro | Tirzepatide | 63 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 20 |
| Bupropion Xl | Bupropion Hcl | 61 | 18 |
| Jardiance | Empagliflozin | 58 | 17 |
| Temazepam | Temazepam | 55 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 53 | 16 |
| Spironolactone | Spironolactone | 52 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 51 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 43 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | 18 |
| Ezetimibe | Ezetimibe | 44 | 15 |
| Synthroid | Levothyroxine Sodium | 44 | 15 |
| Famotidine | Famotidine | 42 | 17 |
| Dutasteride | Dutasteride | 38 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 36 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | 14 |
| Celecoxib | Celecoxib | 35 | 11 |
| Methylprednisolone | Methylprednisolone | 35 | 29 |
| Buspirone Hcl | Buspirone Hcl | 32 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 20 |
| Ondansetron Odt | Ondansetron | 32 | 13 |
| Prednisone | Prednisone | 32 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 31 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 31 | suppressed |
| Levofloxacin | Levofloxacin | 31 | 30 |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 28 | 17 |
| Meclizine Hcl | Meclizine Hcl | 28 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Ramipril | Ramipril | 28 | suppressed |
| Fenofibrate | Fenofibrate | 27 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 25 |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Lorazepam | Lorazepam | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 11 |
| Finasteride | Finasteride | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 16 |
| Diazepam | Diazepam | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Methotrexate | Methotrexate Sodium | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Carisoprodol | Carisoprodol | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 13 |
| Fluconazole | Fluconazole | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Minoxidil | Minoxidil | 13 | suppressed |
| Misoprostol | Misoprostol | 13 | suppressed |
| Trospium Chloride | Trospium Chloride | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $515.67 · 23 records | Abbott Laboratories | AIRSUPRA, CAPVAXIVE, Fluad, Flucelvax, JARDIANCE, Ozempic, REXULTI, Rybelsus, TRINTELLIX, TZIELD, VRAYLAR, WATCHMAN FLX, ZENPEP | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error